Last reviewed 2026-06-01 · How we verify

rhGM-CSF-containing gel

Second Affiliated Hospital of Xi'an Jiaotong University · Phase 1 active Small molecule ✓ Verified Jun 2026 Quality 0/100

rhGM-CSF-containing gel is a Small molecule drug developed by Second Affiliated Hospital of Xi'an Jiaotong University. It is currently in Phase 1 development.

A rhGM-CSF-containing gel is a protein-based treatment that acts as a granulocyte colony-stimulating factor receptor agonist. It has been studied for its effectiveness in promoting recovery after 1927-nm fractional thulium fiber laser treatment of atrophic acne scars and wound healing.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	rhGM-CSF-containing gel
Sponsor	Second Affiliated Hospital of Xi'an Jiaotong University
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effectiveness of a rhGM-CSF-containing Gel on Promoting Recovery After 1927-nm Fractional Thulium Fiber Laser Treatment of Atrophic Acne Scars. (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

rhGM-CSF-containing gel CI brief — competitive landscape report
rhGM-CSF-containing gel updates RSS · CI watch RSS
Second Affiliated Hospital of Xi'an Jiaotong University portfolio CI

Frequently asked questions about rhGM-CSF-containing gel

What is rhGM-CSF-containing gel?

rhGM-CSF-containing gel is a Small molecule drug developed by Second Affiliated Hospital of Xi'an Jiaotong University.

Who makes rhGM-CSF-containing gel?

rhGM-CSF-containing gel is developed by Second Affiliated Hospital of Xi'an Jiaotong University (see full Second Affiliated Hospital of Xi'an Jiaotong University pipeline at /company/second-affiliated-hospital-of-xi-an-jiaotong-university).

What development phase is rhGM-CSF-containing gel in?

rhGM-CSF-containing gel is in Phase 1.

Manufacturer: Second Affiliated Hospital of Xi'an Jiaotong University — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing